Chronic Lung Diseases Treatment Market

By Disease Type;

COPD, Pulmonary Fibrosis, Bronchopulmonary Dysplasia, Asthma and Others

By Treatment Type;

Oxygen Therapy and Drugs

By Distribution Channel;

Drugstores, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and E-Commerce

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn168270138 Published Date: September, 2025 Updated Date: October, 2025

Chronic Lung Diseases Treatment Market Overview

Chronic Lung Diseases Treatment Market (USD Million)

Chronic Lung Diseases Treatment Market was valued at USD 32195.95 million in the year 2024. The size of this market is expected to increase to USD 51699.66 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.0%.


Chronic Lung Diseases Treatment Market

*Market size in USD million

CAGR 7.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.0 %
Market Size (2024)USD 32195.95 Million
Market Size (2031)USD 51699.66 Million
Market ConcentrationMedium
Report Pages321
32195.95
2024
51699.66
2031

Major Players

  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd.
  • Roche Holding AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Bayer AG

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Chronic Lung Diseases Treatment Market

Fragmented - Highly competitive market without dominant players


The Chronic Lung Diseases Treatment Market is expanding rapidly as conditions like COPD, asthma, and pulmonary fibrosis affect nearly 12% of people worldwide. Rising patient awareness about early diagnosis and better disease management is creating a strong demand for innovative treatment approaches. This shift is shaping the industry toward more effective and accessible solutions.

Healthcare Burden and Economic Impact
Chronic respiratory illnesses contribute to about 8% of global healthcare spending, placing a heavy financial load on medical systems. To address this, healthcare providers are focusing on cost-efficient therapies and integrated care pathways. Adoption of digital monitoring tools has shown potential to cut hospitalization rates, reducing treatment expenses by up to 20%.

Innovation in Treatment Approaches
Advances in therapy options, including biologic medicines, smart inhalers, and inhalation drug delivery systems, are transforming the market. Smart inhalers alone have achieved over 15% adoption growth, offering better adherence and outcomes. Biologics targeting specific pathways are proving highly effective in managing severe forms of asthma and COPD.

Shift Toward Preventive Healthcare
Preventive care strategies are becoming central, with nearly 35% of patients experiencing better disease control through early intervention and lifestyle changes. Campaigns promoting smoking cessation, improved air quality, and healthier living environments are further reducing the risks associated with chronic lung diseases.

Growth Prospects and Industry Outlook
The Chronic Lung Diseases Treatment Market is positioned for strong growth, supported by rising healthcare innovation, patient-centered care, and preventive programs. Increasing investments in digital health technologies and biologic research are likely to enhance treatment outcomes and reduce healthcare costs. Collaborative efforts among healthcare providers, pharmaceutical companies, and policymakers will play a pivotal role in shaping the market’s long-term trajectory.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Diseases Type
    2. Market Snapshot, By Treatment Type
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Chronic Lung Diseases Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Prevalence of Chronic Lung Diseases

        2. Technological Advancements in Treatment Modalities

        3. Awareness and Education Initiatives

      2. Restraints
        1. Limited Treatment Efficacy

        2. High Cost of Treatment

        3. Adverse Effects of Treatment

      3. Opportunities
        1. Advancements in Therapeutic Innovation

        2. Personalized Medicine Approaches

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Chronic Lung Diseases Treatment Market, By Diseases Type, 2021 - 2031 (USD Million)
      1. COPD
      2. Pulmonary Fibrosis
      3. Bronchopulmonary Dysplasia
      4. Asthma
      5. Others
    2. Chronic Lung Diseases Treatment Market, By Treatment Type, 2021 - 2031 (USD Million)
      1. Oxygen Therapy
      2. Drugs
    3. Chronic Lung Diseases Treatment Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Drugstores
      2. Hospital Pharmacies
      3. Retail Pharmacies
      4. Online Pharmacies
      5. E-Commerce
    4. Chronic Lung Diseases Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America

        1. United States

        2. Canada

      2. Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Nordic

        7. Benelux

        8. Rest of Europe

      3. Asia Pacific

        1. Japan

        2. China

        3. India

        4. Australia & New Zealand

        5. South Korea

        6. ASEAN (Association of South East Asian Countries)

        7. Rest of Asia Pacific

      4. Middle East & Africa

        1. GCC

        2. Israel

        3. South Africa

        4. Rest of Middle East & Africa

      5. Latin America

        1. Brazil

        2. Mexico

        3. Argentina

        4. Rest of Latin America

  6. Competitive Landscape
    1. AstraZeneca plc
    2. Boehringer Ingelheim International GmbH
    3. GlaxoSmithKline plc
    4. Novartis AG
    5. CHIESI Farmaceutici S.p.A.
    6. Sunovion Pharmaceuticals, Inc.
    7. Teva Pharmaceutical Industries Ltd.
    8. Mylan N.V. (Viatris)
    9. Orion Corporation
    10. Abbott Laboratories
    11. Dr. Reddy’s Laboratories Ltd.
    12. F. Hoffmann-La Roche Ltd.
    13. Sanofi S.A.
    14. Almirall, S.A.
    15. Kyowa Hakko Kirin Co., Ltd.
  • Analyst Views
  • Future Outlook of the Market